Creative Bioarray has announced the launch of its flagship hERG safety assay service, aimed at enhancing drug development by identifying potential cardiotoxic risks in compounds during early research stages. The service addresses a critical pharmaceutical industry challenge where blockage of hERG potassium channels can lead to life-threatening cardiac side effects, making safety assessment paramount for new therapies.
The company utilizes advanced assay methods to assess potential cardiotoxicity of drug candidates, optimizing traditional screening approaches with modern technologies to deliver high-throughput, reliable results. According to Hannah Cole, a spokesperson for Creative Bioarray, the service provides a vital tool for pharmaceutical companies and researchers looking to streamline their drug development process by offering critical information needed to make informed decisions about compound safety.
Creative Bioarray's hERG safety assay can be integrated into early drug development stages, potentially improving project efficiency and helping bring safer drugs to market faster. The company provides clients with detailed data interpretations to help scientists optimize lead compounds while reducing the risk of late-stage development failure due to cardiotoxicity. The service is designed to benefit a wide range of pharmaceutical industry stakeholders, including biotechnology companies, contract research organizations, and academic institutions.
The company has cultivated a team of experienced experts with extensive expertise in pharmacology, electrophysiology, and drug safety assessment, offering not only accurate assays but also comprehensive analysis and guidance throughout the research process. In addition to hERG safety testing, Creative Bioarray offers a range of other bioassays, customized services, and products to meet specific research needs. More information about their services can be found at Creative Bioarray's website.
